These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22825585)

  • 1. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
    van Roon EH; van Puijenbroek M; Middeldorp A; van Eijk R; de Meijer EJ; Erasmus D; Wouters KA; van Engeland M; Oosting J; Hes FJ; Tops CM; van Wezel T; Boer JM; Morreau H
    BMC Cancer; 2010 May; 10():180. PubMed ID: 20444249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
    Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
    Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
    Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer.
    Shigeyasu K; Nagasaka T; Mori Y; Yokomichi N; Kawai T; Fuji T; Kimura K; Umeda Y; Kagawa S; Goel A; Fujiwara T
    PLoS One; 2015; 10(6):e0130409. PubMed ID: 26121593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
    Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
    Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
    Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
    APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
    Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
    Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability and survival in rectal cancer.
    Samowitz WS; Curtin K; Wolff RK; Tripp SR; Caan BJ; Slattery ML
    Cancer Causes Control; 2009 Nov; 20(9):1763-8. PubMed ID: 19669908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.